{"id":842250,"date":"2025-04-25T13:03:27","date_gmt":"2025-04-25T17:03:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/"},"modified":"2025-04-25T13:03:27","modified_gmt":"2025-04-25T17:03:27","slug":"olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/","title":{"rendered":"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancer<\/em>\n        <\/li>\n<li>\n          <em>Patient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in combination regimens in multiple solid tumor types<\/em>\n        <\/li>\n<li>\n          <em>Data to be presented at 2025 AACR Annual Meeting<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>SAN FRANCISCO, April  25, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yyGU0-6nq3kJTJHK6qWmMZZsV_mVXc45BTxXGUSNvkwHBkXRieiMLfxiy5AbrkIvO7yvs1IF6Zg6rXOzZFeAjGe1pFo6EcmDcuHZRNmCb_M=\" rel=\"nofollow\" target=\"_blank\"><u>Olema Pharmaceuticals, Inc.<\/u><\/a> (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data demonstrating the anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer (NSCLC) models. These findings are being presented in a late-breaking poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.<\/p>\n<p>\u201cThese data showcase the potential of OP-3136 for the treatment of challenging cancers beyond breast cancer,\u201d said David C. Myles, Ph.D., Chief Discovery and Non-Clinical Development Officer of Olema Oncology. \u201cOP-3136 has shown inhibition across all models explored, and we were excited to observe potent tumor growth inhibition and sustained tumor regression with OP-3136 as a monotherapy in ovarian cancer models. We are actively recruiting the Phase 1 trial of OP-3136 in multiple solid tumor types and will continue to explore its potential in other indications of high unmet need.\u201d<\/p>\n<p>\n        <em>Poster Presentation Details <\/em><br \/>\n        <br \/>\n        <strong>Title: <\/strong>OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models <br \/><strong>Poster\/Abstract: <\/strong>LB166<br \/><strong>Session:<\/strong> Late-Breaking Research: Tumor Biology 2<br \/><strong>Date\/Time: <\/strong>April 28, 2025, from 9:00am-12:00pm CT \/ 10:00am-1:00pm ET<br \/><strong>Presenter: <\/strong>Dr. Gopinath S. Palanisamy, DVM, Ph.D.<\/p>\n<p>Key findings include:<\/p>\n<ul type=\"disc\">\n<li>OP-3136 showed potent anti-proliferative activity in multiple ovarian, NSCLC, and prostate cell lines in vitro.<\/li>\n<li>OP-3136 showed activity that was independent of KAT6 amplification or over expression.<\/li>\n<li>OP-3136 monotherapy demonstrated anti-tumor activity in <em>in vivo <\/em>xenograft models of ovarian (OVCAR3), NSCLC (LCLC-97TM1), and prostate (22Rv1) cancers.\n<ul type=\"circle\">\n<li>In the OVCAR3 model, OP-3136 monotherapy demonstrated sustained tumor regression across the 28-day study period and robust tumor growth inhibition.<\/li>\n<li>In the LCLC-97TM1 model, OP-3136 monotherapy demonstrated tumor growth inhibition comparable to ribociclib and, when combined with ribociclib, demonstrated synergy and enhanced anti-tumor activity.<\/li>\n<li>In the 22Rv1 model, OP-3136 inhibited tumor growth in a dose-dependent manner and, when combined with docetaxel, resulted in enhanced anti-tumor activity.<\/li>\n<\/ul>\n<\/li>\n<li>These data indicate OP-3136 may be effective in treating ovarian, lung, and prostate cancer indications in addition to breast cancer.<\/li>\n<\/ul>\n<p>A copy of this poster is available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QN9IzIoCDLb5M93xt2IWr4dYlE5aXbtaSFyhKMh36lCi4Ls82AiLR0bBwnlRhuleimRmqIGTXK_DALrMNK-Z2PgLdGf9LUOC3nYskR9eNBA=\" rel=\"nofollow\" target=\"_blank\">Publications<\/a> page of Olema\u2019s website. Additional information can be found on the AACR <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nLRHO9xsnZHGheF1crVnmrkcSl5hjOyT1xpWfDALvkRHBs86jm3mTCqqmlDBVZMT_sK5_ypuWe7Fj_ExNF6wDMDVZdPqPuX_gN5-5Ggxg2YkCJVygi46aXk67jk5d2bSgjGxYQVqoKFM4c_ciW35vg==\" rel=\"nofollow\" target=\"_blank\">Annual Meeting website<\/a>, including abstracts.<\/p>\n<p>\n        <strong>About OP-3136<\/strong><br \/>\n        <br \/>OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies, including palazestrant and cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical trial.<\/p>\n<p>\n        <strong>About Olema Oncology<\/strong><br \/>\n        <br \/>Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_AhogOLHl7ml2axwfrTOAZgp9Su_NQh0HfDj5UYHvDJHafzuaFWKsjBAGTfzUO4NUt1x7llIh9vwH2z8wbRoMg==\" rel=\"nofollow\" target=\"_blank\">www.olema.com<\/a>.<\/p>\n<p>\n        <strong>Media and Investor Relations Contact<\/strong><br \/>\n        <br \/>Courtney O\u2019Konek<br \/>Vice President, Corporate Communications<br \/>Olema Oncology<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K5-bXrlrxvLl6-KCUgtkU8j0ntELDoFt0-ca5jQg8ke7EHxv0Y8h16vl82JhDwrRWMic5gztiwIUDiDy_Q4gXPzljmMqq8UhtfaofvSmJYYnC-dz6wTxYy4wGUwWCOMf1uGrqV7ioL42UAidk6EC10qXGAylBHWbDn2lTWuy7op0dsw-icWu-Fejl7o9AX-9nIu_wDgfbk9bxrmITAOWJ1qM1Ut8bJdZSXdDrq7PSxM=\" rel=\"nofollow\" target=\"_blank\">media@olema.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmJjY2E4YWQtM2VjZi00ZDFhLWFlNmEtYmE4NWJkMjMwMmRkLTEyMTUwNjgtMjAyNS0wNC0yNS1lbg==\/tiny\/Olema-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancer Patient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in combination regimens in multiple solid tumor types Data to be presented at 2025 AACR Annual Meeting SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data demonstrating the anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-842250","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancer Patient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in combination regimens in multiple solid tumor types Data to be presented at 2025 AACR Annual Meeting SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data demonstrating the anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell &hellip; Continue reading &quot;Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-25T17:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025\",\"datePublished\":\"2025-04-25T17:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/\"},\"wordCount\":691,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/\",\"name\":\"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=\",\"datePublished\":\"2025-04-25T17:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/","og_locale":"en_US","og_type":"article","og_title":"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 - Market Newsdesk","og_description":"Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancer Patient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in combination regimens in multiple solid tumor types Data to be presented at 2025 AACR Annual Meeting SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data demonstrating the anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell &hellip; Continue reading \"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-25T17:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025","datePublished":"2025-04-25T17:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/"},"wordCount":691,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/","name":"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=","datePublished":"2025-04-25T17:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzODgyMyM2OTA0ODMwIzIyMDM1MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-aacr-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=842250"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842250\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=842250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=842250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=842250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}